This open-label study evaluated the safety and efficacy of TSC when dosed concomitantly with
the standard of care (radiation therapy and temozolomide) for newly diagnosed glioblastoma in
adults. All patients received TSC in the study. The objective of the study was to evaluate
the effect of TSC on survival and tumor response in patients with GBM while establishing an
acceptable patient risk profile.